

Corewell Health Laboratory

Dearborn • Farmington Hills • Grosse Pointe • Royal Oak • Taylor • Trenton • Troy • Wayne

Discontinuation of Certain Prenatal Screening Tests at Corewell Health East (Beaumont) Laboratory

Effective Date: July 21, 2024

Effective July 21, 2024, the following prenatal screening tests will no longer be performed at Corewell Health East (Beaumont) Laboratory.

DISCONTINUED TESTS	Test Codes
BH FIRST TRIMESTER DOWN'S SCREEN	LAB5775, DOWN1
BH OBSTETRIC QUAD SCREEN	LAB5777, QUAD
BH INTEGRATED OB FIRST TRIMESTER, SERUM	LAB5778, SINT1
BH INTEGRATED OB SCREEN FINAL, SERUM	LAB5779, SINT2
BH FULL INTEGRATED OB, FIRST TRIMESTER	LAB5780, INT1
BH FULL INTEGRATED OB, FINAL	LAB5781, INT2
BH SEQUENTIAL SCREEN, FIRST TRIMESTER	LAB5782, SEQ1
BH SEQUENTIAL SCREEN, FINAL	LAB5783, SEQ2

Note: Maternal serum AFP and amniotic fluid AFP will continue to be performed for open neural tube defect risk assessment.

Background: Risk assessments for prenatal conditions (e.g., Down syndrome, Trisomy 18) are based on having accurate patient result medians for biochemical markers found in maternal serum (AFP, uE3, hCG, Inhibin A, PAPP-A) as well as valid nuchal translucency measurements by ultrasound in the first trimester.

Due to much greater use of cell-free DNA prenatal screening tests, requests for first trimester, integrated, and sequential Down syndrome risk assessments by maternal serum biochemical markers have markedly decreased. Ongoing assessment of patient population medians for each individual marker is necessary for accurate risk assessments; however, with decreased test volumes, determination of patient medians has become more and more statistically uncertain.



Laboratory Bulletin

Corewell Health Laboratory

Dearborn • Farmington Hills • Grosse Pointe • Royal Oak • Taylor • Trenton • Troy • Wayne

A related problem is the recent discontinuation of the Perinatal Quality Foundation's NTQR ultrasonographer credentialing program. This was one of two national programs recognized by the laboratory to approve individual sonographers and incorporate their first-trimester NT measurements into risk assessments. Although Corewell Health East (Beaumont) Laboratory will no longer perform marker testing, client sonographers may still be certified through the Fetal Medicine Foundation (http://www.fetalmedicineusa.com/accreditation.php) in order to submit NT measurements to other laboratories.

If you have questions, please contact your Beaumont Laboratory Customer Service Department:

• Corewell Health Reference Lab Customer Service: 800-551-0488 or 248-551-1155, Option 5

Date submitted: June 7, 2024

Submitted by: Steven M. Truscott, PhD, Technical Director, Clinical Chemistry

Caitlin Schein, MD, System Medical Director